Semaglutide vs. Tirzepatide vs. Retatrutide: The Complete Comparison

For research and educational purposes only. Nothing in this guide constitutes medical advice. Consult a qualified healthcare professional before beginning any new protocol. These compounds are discussed here as research compounds; regulatory status varies by compound and is noted throughout.

Last updated: July 2026

---

Three compounds, one underlying idea, and a genuinely interesting story about what happens when you add one more receptor pathway at a time. Semaglutide proved the concept. Tirzepatide showed what happens when you add a second mechanism. Retatrutide is testing what happens with a third. This guide puts all three side by side — not to declare a winner, but to give you an honest, detailed basis for deciding which one actually fits your research objective.

At a Glance

	Semaglutide	Tirzepatide	Retatrutide
Receptor targets	GLP-1 only	GLP-1 + GIP	GLP-1 + GIP + Glucagon
First approved	2017 (Ozempic)	2022 (Mounjaro)	Not yet approved
Years of real-world data	~9 years	~4 years	None
Weight loss (pivotal trial, longest duration)	~15% at 68 weeks (STEP 1)	~20.9% at 72 weeks (SURMOUNT-1, 15mg)	~28.3% at 80 weeks (TRIUMPH-1, 12mg)
Direct head-to-head data	Lost to tirzepatide (SURMOUNT-5)	Beat semaglutide (SURMOUNT-5)	Not yet tested head-to-head against either
Cardiovascular outcomes	Extensive (SUSTAIN-6, SELECT, SOUL)	Substantial (SURPASS-CVOT, SUMMIT)	None yet
Kidney outcomes	Yes (FLOW trial)	Emerging	None yet
Regulatory status	Fully approved, multiple formulations	Fully approved	NDA filing expected late 2026
Typical community dose (well below trial ceiling)	0.25mg–0.5mg weekly	2.5mg–5mg weekly	1mg–3mg weekly

The Mechanism Difference: One, Two, Three Receptors

All three compounds work by amplifying hormone signals your gut already produces after eating. The difference is how many of those signals each one targets, and that difference isn’t cosmetic — it changes what’s actually happening in the body.

Semaglutide activates one receptor: GLP-1. This suppresses appetite, slows gastric emptying, and improves glucose-dependent insulin release. It’s the foundational mechanism the entire category is built on, and every compound in this comparison uses it as at least part of its own mechanism.

Tirzepatide activates two: GLP-1, plus GIP (glucose-dependent insulinotropic polypeptide). The GIP component does something GLP-1 alone doesn’t — it improves how fat tissue and muscle respond to insulin, and appears to contribute its own independent appetite-suppressing signal through the brain. Critically, the two pathways don’t simply add together; the leading explanation for tirzepatide’s outsized results is that they work synergistically, producing more effect than you’d expect from just “GLP-1 plus a bit more.”

Retatrutide activates three: GLP-1 and GIP, plus glucagon receptor activation. This third pathway is the most mechanistically distinct of the group, because it doesn’t just suppress appetite — it directly increases energy expenditure and fat oxidation, independent of how much someone is eating. Where semaglutide and tirzepatide work almost entirely by getting you to eat less, retatrutide adds a genuine “burning more” component on top of that.

The practical takeaway: this isn’t three versions of the same drug at different strengths. Each addition targets a genuinely separate biological pathway, and the escalating trial results reflect real, distinct mechanisms stacking on top of each other — not just a bigger dose of the same idea.

Efficacy: What the Head-to-Head and Trial Data Actually Show

This is where people most want a simple answer, and the honest answer is “yes, but with an important asterisk about how directly these have actually been compared.”

Semaglutide vs. Tirzepatide has real head-to-head data. SURMOUNT-5, a direct controlled trial, found tirzepatide produced 20.2% average weight loss compared to semaglutide’s 13.7% over the same 72-week period — tirzepatide won on the primary endpoint and every secondary endpoint measured. This is about as clean a comparison as you can get in this category: same trial, same conditions, same duration, different compound.

Retatrutide vs. either compound does not have head-to-head data yet. Its headline number — 28.3% weight loss at 80 weeks in TRIUMPH-1 — comes from a separate trial with its own population, timeline, and design. It’s larger than tirzepatide’s number, but it hasn’t been tested against tirzepatide or semaglutide directly in the way SURMOUNT-5 tested tirzepatide against semaglutide. Cross-trial comparisons are suggestive, not conclusive — differences in study population, trial length, and methodology can all move the numbers around independent of the compound itself.

So the accurate hierarchy, stated carefully: tirzepatide has demonstrated superiority over semaglutide in a genuine head-to-head trial. Retatrutide has produced the largest numbers of the three across separate trials, but that specific claim — “retatrutide beats tirzepatide” — remains a reasonable inference from the available data rather than a directly proven result.

Evidence Maturity: The Tradeoff Nobody Puts on the Label

Here’s the pattern that matters as much as the efficacy numbers: potency has gone up with each compound, and evidence maturity has gone down. This is the single most important framework for thinking about this category.

Semaglutide has nine years of real-world use, a full spread of outcomes data (cardiovascular, kidney, and now heart failure-specific findings), and the kind of accumulated safety experience that only comes from millions of patients over the better part of a decade. It gives up raw effect size in exchange for being the most thoroughly de-risked option in the category.

Tirzepatide has closed a lot of ground on evidence maturity faster than most people expected. SURPASS-CVOT (published December 2025) and SUMMIT (heart failure, November 2024) gave it substantial cardiovascular and heart-failure outcome data in a relatively short window — this genuinely was “the more powerful but less proven option” as recently as a year or two ago, and that characterization is now noticeably less true than it was.

Retatrutide has the least real-world grounding of the three, by definition, since it isn’t approved anywhere yet. Its Phase 3 data across multiple populations (general obesity, type 2 diabetes, knee osteoarthritis) has been consistently positive, but there’s no cardiovascular outcomes trial completed, no kidney outcomes data, and zero years of the kind of post-marketing experience that eventually surfaces rare or long-term effects that trials of any size can miss.

Safety and Outcomes Data, Compared Directly

Beyond weight loss, each compound has built a different depth of evidence for what it protects against, or fails to yet demonstrate.

Cardiovascular protection: Semaglutide has the deepest bench here — SUSTAIN-6 (2016) established the original signal, SELECT (2023) extended it to a non-diabetic population, and SOUL (2024, with a 2026 heart-failure-specific follow-up) added further outcomes data in high-risk patients. Tirzepatide’s SURPASS-CVOT (2025) found comparable protection against major cardiac events in a head-to-head trial against another GLP-1 drug, putting it on genuinely similar footing for this specific outcome. Retatrutide has no cardiovascular outcomes data of any kind yet.

Kidney protection: Semaglutide is the only one of the three with a dedicated, completed kidney-outcomes trial — FLOW, which supported a 2025 label expansion for reducing kidney disease progression. Neither tirzepatide nor retatrutide has an equivalent trial completed as of this writing.

Heart failure specifically: Tirzepatide’s SUMMIT trial is the most direct and positive heart-failure-specific finding among the three, showing a 38% reduction in worsening heart failure events in a population with preserved ejection fraction. Semaglutide’s SOUL follow-up found a related but somewhat narrower benefit in patients who already had heart failure. Retatrutide has no data here.

Side Effects: How Different Are They, Really?

Despite the escalating potency, the side effect profiles across all three compounds are more similar than the efficacy differences might suggest. Nausea, decreased appetite, vomiting, diarrhea, and constipation are the dominant side effects for all three, concentrated most heavily during titration and dose increases, and generally easing over four to eight weeks as the body adapts.

What does change somewhat is intensity at the extremes: retatrutide’s triple mechanism produces a more pronounced initial physiological response than the other two at equivalent stages of titration, and community and trial reporting both suggest that rushing its titration schedule carries a higher cost in GI side effects than doing the same with semaglutide. Tirzepatide sits close to semaglutide in reported tolerability at equivalent titration stages, despite its larger effect size — potency and side effect burden haven’t scaled together as directly as you might expect.

Which One Actually Fits Your Research Objective?

There’s no universally correct choice here — the right compound depends on what you’re actually optimizing for.

Choose semaglutide if: maximum evidence maturity and the deepest cardiovascular and kidney safety data matter more to you than raw effect size. It’s the most conservative, most de-risked choice of the three, backed by the longest track record in the category.

Choose tirzepatide if: you want meaningfully stronger documented efficacy than semaglutide, and you’re comfortable with a shorter but still substantial and rapidly maturing safety record. For many researchers, this is the practical middle ground — real, head-to-head-proven superiority over semaglutide, with cardiovascular and heart-failure evidence that’s caught up faster than expected.

Choose retatrutide if: maximum documented effect size is the priority, and you’re comfortable being an early adopter of a compound with no approval, no long-term real-world safety data, and no outcomes trials of any kind yet. This is a legitimate, evidence-informed choice — the Phase 3 data is genuinely strong — but it’s a different kind of choice than the other two, closer to being at the frontier of what’s known rather than building on nearly a decade of accumulated confidence.

None of these are wrong answers. They’re different answers to different questions about how much you’re willing to trade evidence certainty for effect size.

Common Questions

Is retatrutide really “the strongest,” or is that overstated? Its trial numbers are the largest of the three, and that’s a fair, accurate statement. What’s overstated is treating that as a settled, head-to-head-proven fact the way tirzepatide’s superiority over semaglutide actually is — retatrutide’s numbers come from separate trials, not a direct comparison.

If tirzepatide beat semaglutide in a real trial, why would anyone still choose semaglutide? Evidence maturity. Nine years of real-world use, a completed kidney-outcomes trial, and the longest cardiovascular data set in the category are real advantages that a stronger effect size doesn’t automatically outweigh, especially for a researcher prioritizing safety certainty over maximum results.

Will retatrutide eventually have a head-to-head trial against tirzepatide? None has been announced as of this writing. Until one exists, any specific claim that retatrutide beats tirzepatide head-to-head is an inference from separate trials, not a demonstrated result.

Do these compounds get combined with each other? No — combining multiple compounds from the same receptor-agonist class isn’t a documented or supported approach, and tirzepatide’s own labeling specifically notes it shouldn’t be combined with other GLP-1 receptor agonists.

Which one has the mildest side effects? None is clearly mildest — GI side effects during titration are the dominant experience across all three. Retatrutide’s triple mechanism does appear to produce a somewhat stronger initial response at equivalent titration stages, making patient titration especially important for that compound specifically.

Where to Go From Here

• Semaglutide: The Complete Guide
• Tirzepatide: The Complete Guide
• Retatrutide: The Complete Guide
• Preserving Lean Mass During a GLP-1 Protocol
• Our Reconstitution and Storage Guide
• Our Certificate of Analysis and Vendor Verification Guide

---

This guide reflects the evidence and community research patterns available as of publication and will be updated periodically as new research emerges. It is provided for research and educational purposes only, does not constitute medical advice, and is not a substitute for consultation with a qualified healthcare professional. Aethon Labs does not intend for any compound discussed here to be used for human consumption.

AETHON LABS — Tested. Documented. Delivered.